Pin It
via MediPen

A cannabis product is being tested by the NHS

The cannabidiol vaporiser marks a first for the UK public body testing the medical benefits of cannabis

An NHS unit is testing a cannabidiol vaporiser, the first cannabis product ever tested by the public body, which could hugely impact surrounding UK legislation if its medical benefits can be evidenced.

In a report by the Independent, they found that the producers of MediPen had been consulting with NHS production and regulatory support pharmacists in the last few months as they test cannabis oil formulation and its properties.

MediPen is a legal way to consume cannabidiol (CBD), which is oil extracted from the cannabis plant, and it’s non-psychoactive, unlike THC. The company have had the product on sale for a year, with users treating the likes of depression, anxiety and fibromyalgia.

According to MediPen, a public report on the testing process and extraction methodology is on its way, detailing levels of purity and its properties.

Managing director Jordan Own told the Independent: “Over the past year the MediPen has quickly become without a doubt one of the most highly-rated CBD products in the world. We’ve recently been working very closely with a team of NHS production and regulatory support pharmacists who've been able to meticulously analyse our proprietary formulation for both safety and cannabinoid concentration. 

“As the UK’s industry leading consumer cannabis biotechnology company, we’re excited to have set a new benchmark in providing a much-needed sense of legitimacy to the UK’s rapidly growing legal cannabis industry.

“As the first consumer cannabis product to be tested by the NHS, we are confident that this will go a long way towards creating a properly regulated cannabis market in the UK and are extremely excited to see what the future holds.”

The NHS didn’t comment as a non-disclosure agreement prevents sharing any client information unless it’s a public body.

Last year, a petition calling to legalise cannabis reached more than 230,000 signatures. It was debated in parliament but later dismissed. However, this latest venture by the NHS could prove to be the opener to a more open approach to the drug, as well as fostering a medical marijuana industry that parts of the U.S benefit from.